Efficacy and safety of tenofovir alafenamide fumarate in treatment of chronic hepatitis B patients aged ≥60 years in Qingdao, China

Yuwen SONG; Lizhen CHEN; Wenwen JIN; Ning GENG; Yang ZHANG; Shuixian DU; Bentian ZHAO; Jianping DUAN; Yong ZHOU; Chunhua BI; Lei MA; Xinxin HU; Jihong ZHANG; Jiantao SUN; Jie TAN; Yongning XIN

doi:10.3969/j.issn.1001-5256.2023.05.010

Volume 39 Issue 5

May 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(5): 1061-1069

PDF( 2730 KB)

Efficacy and safety of tenofovir alafenamide fumarate in treatment of chronic hepatitis B patients aged ≥60 years in Qingdao, China

DOI: 10.3969/j.issn.1001-5256.2023.05.010

1.
Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, Shandong 266000, China
2.
Department of Infectious Diseases, Qingdao Sixth People's Hospital, Qingdao, Shandong 266000, China
3.
Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China
4.
Department of Infectious Diseases, Chengyang People's Hospital, Qingdao, Shandong 266000, China
5.
Department of Infectious Diseases, Jimo People's Hospital, Qingdao, Shandong 266000, China

Research funding:

Chronic Hepatitis B Clinical Research Project (IN-CN-320-5837)

More Information

Corresponding author: XIN Yongning, xinyongning@163.com (ORCID: 0000-0002-3692-7655)
Received Date: 2022-10-25
Accepted Date: 2022-12-02
Published Date: 2023-05-20

Abstract

Abstract

Objective To investigate the application value of tenofovir alafenamide fumarate (TAF) in elderly patients with chronic hepatitis B (CHB) and its influence on bones and kidneys. Methods A total of 36 CHB patients, aged ≥60 years, who received TAF antiviral therapy in Qingdao Municipal Hospital, The Affiliated Hospital of Qingdao University, Qingdao Sixth People's Hospital, Chengyang People's Hospital, and Jimo People's Hospital from June 2021 to October 2022 were enrolled in this study, and all patients received TAF (25 mg/d) antiviral therapy. Related data were collected at baseline and weeks 24 and 48 of treatment, including virological indicators, biochemical parameters, urinary protein electrophoresis indices, transient elastography (FibroScan), and bone mineral density. Virological indicators included high-sensitivity HBV DNA quantification; biochemical parameters included total bilirubin, direct bilirubin (DBil), indirect bilirubin (IBil), alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bile acid (TBA), glucose, blood urea nitrogen, creatinine, estimated glomerular filtration rate, and cystatin C (Cys C); urinary protein electrophoresis indices included urinary β2 microglobulin (β2-MG), urinary retinol (URBP), and urinary α1 microspherin (α1-MG). The paired t-test was used for comparison of normally distributed continuous data before and after treatment, and the Wilcoxon signed-rank test was used for comparison of non-normally distributed continuous data before and after treatment; the chi-square test or the Fisher's exact test was used for comparison of categorical data. Results A total of 36 CHB patients completed 24 weeks of follow-up. The complete virological response rate after 24 weeks of treatment was higher than that at baseline [83.3% (30/36) vs 77.8% (28/36), χ²=0.36, P=0.55], and there were significant reductions in DBil (t=-2.42, P=0.02) and Cys C (t=-4.34, P < 0.001) from baseline to week 24. A total of 18 CHB patients completed 48 weeks of follow-up. The complete virological response rate after 48 weeks of treatment was higher than that at baseline (94.4% vs 77.8%, χ²=2.22, P=0.34), and there were significant increases in IBil (t=2.43, P=0.03), TBA (Z=-2.24, P=0.03), and bone mineral density T score of lumbar vertebra (t=2.92, P= 0.01) and femoral neck (t=2.42, P=0.03) and a significant reduction in liver stiffness measurement (t=-2.31, P=0.03). There were no significant changes in β2-MG, URBP, and α1-MG after treatment (all P > 0.05). Conclusion TAF has a good antiviral effect in CHB patients aged ≥60 years and can help more CHB patients achieve complete virological response, without causing damage to the kidney, and it can also improve bone mineral density and liver fibrosis degree.
- Hepatitis B, Chronic,
- Tenofovir Alafenemide Fumarate,
- Treatment Outcome,
- Aged

FullText(HTML)

References(17)

References

[1]	WANG H, MEN P, XIAO Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis[J]. BMC Infect Dis, 2019, 19(1): 811. DOI: 10.1186/s12879-019-4428-y.
[2]	LIU J, ZHANG S, WANG Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study[J]. Lancet Infect Dis, 2016, 16(1): 80-86. DOI: 10.1016/S1473-3099(15)00218-2.
[3]	LIU Z, LI M, HUTTON DW, et al. Impact of the national hepatitis B immunization program in China: a modeling study[J]. Infect Dis Poverty, 2022, 11(1): 106. DOI: 10.1186/s40249-022-01032-5.
[4]	ZHU JY, GAO M, SONG QY, et al. Prevalence of osteoporosis in Chinese elderly people: a Meta-analysis[J]. Chin Gen Pract, 2022, 25(3): 346-353. DOI: 10.12114/j.issn.1007-9572.2021.02.083 朱洁云, 高敏, 宋秋韵, 等. 中国老年人骨质疏松症患病率的Meta分析[J]. 中国全科医学, 2022, 25(3): 346-353. DOI: 10.12114/j.issn.1007-9572.2021.02.083
[5]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[6]	AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.
[7]	Compilation committee of Chinese expert consensus on medical nutritional therapy for overweight/obesity. Chinese expert consensus on medical nutritional therapy for overweight/obesity (2016)[J]. Chin J Diabetes Mellitus, 2016, 8(9): 525-540. DOI: 10.3760/cma.j.issn.1674-5809.2016.09.004. 中国超重肥胖医学营养治疗专家共识编写委员会. 中国超重/肥胖医学营养治疗专家共识(2016年版)[J]. 中华糖尿病杂志, 2016, 8(9): 525-540. DOI: 10.3760/cma.j.issn.1674-5809.2016.09.004.
[8]	NGUYEN MH, ATSUKAWA M, ISHIKAWA T, et al. Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir[J]. Am J Gastroenterol, 2021, 116(6): 1264-1273. DOI: 10.14309/ajg.0000000000001157.
[9]	FONG TL, LEE BT, TIEN A, et al. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide[J]. J Viral Hepat, 2019, 26(5): 561-567. DOI: 10.1111/jvh.13053.
[10]	LEE BT, CHANG M, LIM C, et al. Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients[J]. JGH Open, 2021, 5(2): 258-263. DOI: 10.1002/jgh3.12481.
[11]	BUTI M, GANE E, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206. DOI: 10.1016/S2468-1253(16)30107-8.
[12]	CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195. DOI: 10.1016/S2468-1253(16)30024-3.
[13]	PAPATHEODORIDIS GV, MIMIDIS K, MANOLAKOPOULOS S, et al. HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks[J]. Aliment Pharmacol Ther, 2022, 56(4): 702-712. DOI: 10.1111/apt.17093.
[14]	SURIAL B, BEGUELIN C, CHAVE JP, et al. Brief report: switching from TDF to TAF in HIV/HBV-coinfected individuals with renal dysfunction-a prospective cohort study[J]. J Acquir Immune Defic Syndr, 2020, 85(2): 227-232. DOI: 10.1097/QAI.0000000000002429
[15]	LUO X, QU Y, CAI XB, et al. Effects of antiviral therapy on the reversal of liver fibrosis[J]. J Clin Hepatol, 2022, 38(11): 2596-2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032. 罗昕, 曲颖, 蔡晓波, 等. 抗病毒治疗对肝纤维化逆转的影响[J]. 临床肝胆病杂志, 2022, 38(11): 2596-2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032.
[16]	CHEN P, WEI W, JIN L, et al. Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B[J]. Exp Ther Med, 2021, 22(5): 1325. DOI: 10.3892/etm.2021.10760.
[17]	LI C, MA Y, YANG C, et al. Association of cystatin C kidney function measures with long-term deficit-accumulation frailty trajectories and physical function decline[J]. JAMA Netw Open, 2022, 5(9): e2234208. DOI: 10.1001/jamanetworkopen.2022.34208.

Relative Articles

[1]	Shipeng MA, Yanqing YU, Xiaoping WU, Liang WANG, Liping LIU, Yuliang ZHANG, Xin WAN, Shanfei GE. Changes in renal function in chronic hepatitis B patients treated initially with entecavir versus tenofovir alafenamide fumarate and related influencing factors[J]. Journal of Clinical Hepatology, 2025, 41(1): 44-51. doi: 10.12449/JCH250107
[2]	Long CHENG, Yue ZHANG, Yushen LIU, Zhaoqing DU, Zhaoyang GUO, Yangwei FAN, Ting LI, Xu GAO, Enrui XIE, Zixuan XING, Wenhua WU, Yinying WU, Mingbo YANG, Jie LI, Yu ZHANG, Wen KANG, Wenjun WANG, Fanpu JI, Jiang GUO, Ning GAO. Efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(10): 2034-2041. doi: 10.12449/JCH241017
[3]	Qian XUE, Chunling JIA, Jingtong WANG. Association between nonalcoholic fatty liver disease and osteoporosis in elderly patients[J]. Journal of Clinical Hepatology, 2024, 40(8): 1585-1590. doi: 10.12449/JCH240813
[4]	Journal of Viral Hepatitis｜Efficacy and safety of tenofovir amibufenamide and tenofovir alafenamide for first-time HBV-related decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(12): 2449-2449. doi: 10.12449/JCH2412.gwqkjpwzjj3
[5]	Xinxin RONG, Yuanyuan XU, Guangde YANG, Xia WANG, Juanjuan FU, Li LI, Xiucheng PAN. Efficacy and safety of tenofovir alafenamide fumarate in patients with first-time hepatitis B virus-related decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(10): 2008-2013. doi: 10.12449/JCH241013
[6]	Jinhan ZHAO, Jing ZHANG, Yang ZHANG, Xiaoyi XU, Yusong GOU, Hangfei XU, Yan WAN, Jian WU. Association between the rs1800591 variation of the microsomal triglyceride transfer protein gene and the risk of nonalcoholic fatty liver disease in the elderly population[J]. Journal of Clinical Hepatology, 2023, 39(3): 552-561. doi: 10.3969/j.issn.1001-5256.2023.03.011
[7]	Haiyang ZANG, Weina LI, Shousheng LIU, Yong ZHOU, Yongning XIN. Predictive factors for functional cure after sequential therapy with nucleos(t)ide analogues and pegylated interferon alfa-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(2): 299-306. doi: 10.3969/j.issn.1001-5256.2023.02.008
[8]	Yuwen SONG, Lili SHA, Lizhen CHEN, Mengkun LI, Yurong WANG, Yongning XIN. Research advances in tenofovir alafenamide fumarate in treatment of special chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(1): 156-161. doi: 10.3969/j.issn.1001-5256.2023.01.024
[9]	Rui LU, Shuangsuo DANG, Yixin LIU, Yikai WANG, Chenrui LIU, Yaping LI, Fengping WU, Mei LI. Dynamic changes of serum hepatitis B virus DNA and HBsAg in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate for 3 years[J]. Journal of Clinical Hepatology, 2022, 38(10): 2224-2229. doi: 10.3969/j.issn.1001-5256.2022.10.006
[10]	Hailin CHENG, Xudong HU, Bing XIA, Tao BAI, Sixia LU. Clinical effect of tenofovir alafenamide fumarate on chronic hepatitis B patients with low viral load after entecavir treatment[J]. Journal of Clinical Hepatology, 2022, 38(3): 537-540. doi: 10.3969/j.issn.1001-5256.2022.03.009
[11]	Jiang Hua, Wang YueHua, Liu JiaFeng, Liu DongBin, Zheng YaMin. Experience of individualized radiofrequency ablation in patients aged 65 years or older with liver tumors[J]. Journal of Clinical Hepatology, 2020, 36(2): 404-405. doi: 10.3969/j.issn.1001-5256.2020.02.035
[12]	Cheng Si, Chen Bao, Xu Nie. A case of recurrent hilar cholangiocarcinoma in the elderly treated with anlotinib[J]. Journal of Clinical Hepatology, 2020, 36(6): 1349-1350. doi: 10.3969/j.issn.1001-5256.2020.06.032
[13]	Wang SuNa, Lian JianQi, Jia ZhanSheng, Zhang Ying. Research advances in the clinical effect of tenofovir alafenamide in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(8): 1828-1833. doi: 10.3969/j.issn.1001-5256.2019.08.040
[14]	Huang YongJie, Wu DeQuan, Yuan JunHui. Current status of treatment of primary hepatocellular carcinoma in the elderly population[J]. Journal of Clinical Hepatology, 2018, 34(6): 1313-1317. doi: 10.3969/j.issn.1001-5256.2018.06.039
[15]	Duan RenQuan, Wang Wei, Zhang HuiHui, Liang JingJing, Tang LuLu. Clinical effect of laparoscopic biliary reoperation in treatment of elderly patients with extrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(2): 289-292. doi: 10.3969/j.issn.1001-5256.2017.02.017
[16]	Tao Ping, Wu XiangYang, Zhang Lei. Clinical effect of ultrasound-guided percutaneous transhepatic gallbladder drainage in treatment of acute cholecystitis in elderly patients[J]. Journal of Clinical Hepatology, 2016, 32(10): 1929-1931. doi: 10.3969/j.issn.1001-5256.2016.10.021
[17]	Wang YuLin, Hu RongKui, Zong Min. Diagnosis and treatment of pyogenic liver abscess in elderly patients by multislice CT[J]. Journal of Clinical Hepatology, 2015, 31(1): 103-106. doi: 10.3969/j.issn.1001-5256.2015.01.022
[18]	Cai ShaoPing, Zhang WenJin, He WeiPing, Fan ZhenPing, Ji YingJie. Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 69-71. doi: 10.3969/j.issn.1001-5256.2014.01.019
[19]	Zhou XianShan, Hong HuiLan. Clinical analysis of elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2008, 24(5): 364-366.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	王一涵，孙怀聪，裴德霖，孙诗涵，陈岚芳，王勇. 海南省肝癌风险预测模型的建立与评价. 海南医学. 2024(17): 2438-2442 .
2.	周荃，杨丽晖，蒋芳清. 直接抗病毒药物改善HCV相关肝细胞癌患者远期预后效果的Meta分析. 临床肝胆病杂志. 2021(08): 1836-1840 . 本站查看
3.	赵小军. 红细胞体积分布宽度与血小板比值在慢性乙型肝炎患者肝纤维化评估中的临床价值. 检验医学与临床. 2021(15): 2278-2281 .
4.	宋晓玲，顾钧，刘颖斌. 菌群紊乱对肝胆肿瘤影响的研究进展. 中华消化外科杂志. 2020(12): 1336-1340 .